logo

VENUSREM vs WOCKPHARMA: Stock Comparison

VENUSREM vs WOCKHARDTUpdated 1 Oct 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. VENUSREM shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

VENUSREM leads 11; WOCKPHARMA leads 0 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

VENUSREMWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹1,924 Cr
₹30,126 Cr
P/E RatioVENUSREM has the lower reading
16.56x ✓
73.66x
P/B RatioVENUSREM has the lower reading
2.9x ✓
6.1x
EPSVENUSREM has the higher reading
₹17.18 ✓
₹6.52
Book ValueContext only
₹496.56
₹325
Dividend YieldVENUSREM has the higher reading
0.66% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,126 Cr vs ₹1,924 Cr
P/E Ratio
VENUSREM has a lower P/E
16.56x vs 73.66x
P/B Ratio
VENUSREM has a lower P/B
2.9x vs 6.1x
EPS
VENUSREM has higher earnings per share
₹17.18 vs ₹6.52
Dividend Yield
VENUSREM has a higher dividend yield
0.66% vs 0%
Revenue Growth (TTM YoY)
VENUSREM has faster revenue growth
33% vs 26%
EPS Growth (TTM YoY)
VENUSREM has faster EPS growth
126.4% vs 0%
ROE
VENUSREM has a higher ROE
15.49% vs 3.77%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricVENUSREMWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricVENUSREMWOCKPHARMA
Live Price₹1,796.7₹1,855.5
Day Change0.03%-1.16%
Volume1.17 L4.57 L
52-Week High₹1,880₹2,422.3
52-Week Low₹432.1₹1,086.7
Distance from 52W High-4.43%-23.4%

Valuation

MetricVENUSREMWOCKPHARMA
Market Cap₹1,924 Cr₹30,126 Cr
P/E Ratio16.56x73.66x
P/B Ratio2.9x6.1x
EPS₹17.18₹6.52
Book Value₹496.56₹325
Dividend Yield0.66%0%

Growth

MetricVENUSREMWOCKPHARMA
Revenue Growth (TTM YoY)33%26%
EPS Growth (TTM YoY)126.4%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricVENUSREMWOCKPHARMA
ROE15.49%3.77%
ROCE16.2%5.44%
Net Margin13.35%3.3%
Operating Margin17.56%13.37%
Debt to Equity0x0.4x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricVENUSREMWOCKPHARMA
Promoter Holding41.76%49.08%
FII Holding3.14%▲ 0.22 pp7.22%▲ 0.13 pp
DII Holding0.74%▼ 0.15 pp9.24%▼ 1.72 pp
Public Holding54.36%▼ 0.07 pp34.44%▲ 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: VENUSREM and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.